Renalytix AI plc

General Information
Business:

(Note: A public offering: Our ordinary shares trade on AIM, a market operated by the London Stock Exchange, under the symbol “RENX.” The last reported sale price of our ordinary shares on AIM on July 10, 2020 was £5.70 per ordinary share, equivalent to a price of $14.22 per ADS, based on an exchange rate of $1.2469 per £1.00 as of July 2, 2020 and an ADS-to-share ratio of 1-to-2.)

We are an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs. KidneyIntelX, our first-in-class diagnostic platform, employs a proprietary artificial intelligence-enabled algorithm that combines diverse data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record, or EHR, systems, to generate a unique patient risk score. 

 

Industry: MEDICAL LABORATORIES
Employees: 14
Founded: 2018
Contact Information
Address Avon House 19 Stanwell Road Penarth, Cardiff CF64 2EZ United Kingdom
Phone Number +44 20 3139 2910
Web Address http://www.renalytixai.com
View Prospectus: Renalytix AI plc
Financial Information
Market Cap
Revenues $0 mil (last 12 months)
Net Income $-9.0 mil (last 12 months)
IPO Profile
Symbol RNLX
Exchange NASDAQ
Shares (millions): 5.5
Price range $13.50 - $13.50
Est. $ Volume $74.1 mil
Manager / Joint Managers J.P. Morgan/ Stifel
CO-Managers -
Expected To Trade: 7/17/2020
Status:
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change